ArticleSaudi medical journal2017
Serologic evidence of Toxoplasma gondii infection among cancer patients. A prospective study from Qassim region, Saudi Arabia.
Article in Saudi medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
- Serological and molecular detection of Toxoplasma Gondii among cancer patients in Sohag, Upper Egypt: a case-control study.Scientific reports · 2025Article
- The effect of infection withArchives of Razi Institute · 2024Article
- Seroprevalence ofPeerJ · 2022Article
- Increased Risk ofBioMed research international · 2020Article
- Transcriptome Sequencing Investigated the Tumor-Related Factors Changes AfterFrontiers in microbiology · 2019Article
- Seroprevalence and risk factors of Toxoplasma gondii infection in oral cancer patients in China: a case-control prospective study.Epidemiology and infection · 2018Article
- Comment to: Serologic evidence of Toxoplasma gondii infection among cancer patients. A prospective study from Qassim region, Saudi Arabia.Saudi medical journal · 2017Article
- Seroprevalence of Anti-Iranian journal of parasitologyArticle
- Toxoplasmosis in immunocompetent Saudi women: Correlation with vitamin D.Women's health (London, England)Article
- Serum Levels of Il-12 and Il-23 in Breast Cancer Patients Infected withIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the frequency of antibody seropositivity of Toxoplasma gondii infection in a cancer patient population. We also explored on association of Toxoplasma gondii seropositivity with selected variables. Methods: This is a prospective cross-sectional study conducted at Prince Faisal bin Bandar cancer center, Qassim, Saudi Arabia, from November 2014 to March 2015. One hundred thirty seven patients were involved in the study. Demographic data was collected using structured questionnaire, and clinical information was retrieved from the patient's medical reports. Enzyme-linked immunosorbent assay technique was used for antibody assay. Results: The frequency of seropositivity for Toxoplasma gondii infection was 30.6%. The patient's age range from 1.5-84 years with a geometric mean of 42.7 years. The seropositivity was significantly higher (p<0.05) among the 40-80 years age group (71.4%) as compared to 0-39 years one (28.6%). Conclusion: The prevalence of Toxoplasma gondii increases with increasing age among cancer patients in this region of central Saudi Arabia. More research is advisable for better understanding of ageing in pathogenesis of toxoplasmosis among patients with malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.